AI Article Synopsis

  • This study focused on the economic and health impacts of third-generation cephalosporin-resistant bloodstream infections (3GC-R BSI) in adult patients in Blantyre, Malawi, highlighting the need for cost data in low- and middle-income regions.
  • It found that the average health provider cost for patients with 3GC-R BSI was about $110.27, higher than those with susceptible infections, and patients faced additional costs for medical and non-medical needs.
  • Overall, 3GC-R BSI led to significant societal costs and a substantial loss in quality-adjusted life years (QALYs), accounting for 84% of costs and 82% of QALYs lost related

Article Abstract

Data which accurately enumerate the economic costs of antimicrobial resistance (AMR) in low- and middle- income countries are essential. This study aimed to quantify the impact of third-generation cephalosporin resistant (3GC-R) bloodstream infection (BSI) on economic and health related quality of life outcomes for adult patients in Blantyre, Malawi. Participants were recruited from a prospective, longitudinal cohort study of hospitalised patients with bloodstream infection caused by Enterobacterales at Queen Elizabeth Central Hospital (QECH). Primary costing studies were used to estimate the direct medical costs associated with the inpatient stay. Recruited participants were asked about direct non-medical and indirect costs associated with their admission and their health-related quality of life was measured using the EuroQol EQ-5D questionnaire. Multiple imputation was undertaken to account for missing data. Costs were adjusted to 2019 US Dollars. Cost and microbiology surveillance data from QECH, Blantyre was used to model the annual cost of, and quality-adjusted life years lost to, 3GC-R and 3GC-Susceptible BSI from 1998 to 2030 in Malawi. The mean health provider cost per participant with 3GC-R BSI was US$110.27 (95%CR; 22.60-197.95), higher than for those with 3GC-S infection. Patients with resistant BSI incurred an additional indirect cost of US$155.48 (95%CR; -67.80, 378.78) and an additional direct non-medical cost of US$20.98 (95%CR; -36.47, 78.42). Health related quality of life outcomes were poor for all participants, but participants with resistant infections had an EQ-5D utility score that was 0.167 (95% CR: -0.035, 0.300) lower than those with sensitive infections. Population level burden estimates suggest that in 2016, 3GC-R accounted for 84% of annual societal costs from admission with bloodstream infection and 82% of QALYs lost. 3GC-R bloodstream infection was associated with higher health provider and patient level costs than 3GC-S infection, as well as poorer HRQoL outcomes. We demonstrate a substantial current and future economic burden to society as a result of 3GC-R E. coli and Klebsiella spp. BSI, data urgently needed by policy makers to provide impetus for implementing strategies to reduce AMR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287011PMC
http://dx.doi.org/10.1371/journal.pgph.0001589DOI Listing

Publication Analysis

Top Keywords

bloodstream infection
20
quality life
16
life outcomes
12
population level
8
level costs
8
health-related quality
8
third-generation cephalosporin
8
cephalosporin resistant
8
blantyre malawi
8
3gc-r bloodstream
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!